EQL Share Price Performance
SEK 25.00
-56.30 (-69.25%)
50.0% undervalued intrinsic discount
SEK 50.00
Fair Value
Price SEK 25.00
AnalystConsensusTarget SEK 50.00
Mandelman SEK 86.37
Fair ValueSEK 50.00
Share Pricen/a
EQL Pharma AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
EQL Community Narratives
AN
Fair Value
·Fair Value SEK 50 50.0% undervalued intrinsic discount
European Market Expansion And Pipeline Development Will Unlock Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MA
Fair Value
·Fair Value SEK 86.37 71.1% undervalued intrinsic discount
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
EQL Pharma is pushing hard to expand its range of everyday medicines, with a growing lineup of new products that could keep sales climbing fast. The catch is that the shares already reflect a lot of optimism, and execution plus cash flow need to keep up for the story to work.Read more
MA
SEK 86.37
71.1% undervalued intrinsic discount
Fair Value
Revenue
21.49% p.a.
Profit Margin
15%
Future PE
25x
Price in 2029
SEK 115.56
European Market Expansion And Pipeline Development Will Unlock Potential
EQL Pharma is pushing beyond the Nordics into much larger European markets, betting that its growing lineup of generic medicines can drive the next leg of growth. The upside hinges on successfully launching and supplying new products in tougher, price-driven markets while managing debt and avoiding regulatory or supply-chain setbacks.Read more
AN
SEK 50
50.0% undervalued intrinsic discount
Fair Value
Revenue
25% p.a.
Profit Margin
14.08%
Future PE
14.92x
Price in 2029
SEK 57.31
Trending Discussion
No trending discussion available.
Recently Updated Narratives
MA
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
Fair Value: SEK 86.37 71.1% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EQL: European Rollout And New UTI Therapy Will Drive Future Upside
Fair Value: SEK 50 50.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
EQL Pharma AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.48
- 31.11%
- -3.25%
- 183.7%
About EQL
- Founded
- 2006
- Employees
- 65
- CEO
- WebsiteView website
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
